Home/Filings/4/0000805928-22-000033
4//SEC Filing

Sandberg Eric 4

Accession 0000805928-22-000033

CIK 0000805928other

Filed

Mar 17, 8:00 PM ET

Accepted

Mar 18, 4:10 PM ET

Size

14.3 KB

Accession

0000805928-22-000033

Insider Transaction Report

Form 4
Period: 2022-03-16
Sandberg Eric
Chief Commercial Officer
Transactions
  • Exercise/Conversion

    Restricted Stock Units

    2022-03-166,0006,000 total
    Common Stock (6,000 underlying)
  • Award

    Employee Stock Option (right to purchase)

    2022-03-16+60,57660,576 total
    Exercise: $10.25Exp: 2032-03-16Common Stock (60,576 underlying)
  • Exercise/Conversion

    Common Stock

    2022-03-16+6,00014,310 total
  • Award

    Restricted Stock Units

    2022-03-16+62,91062,910 total
    Common Stock (62,910 underlying)
  • Tax Payment

    Common Stock

    2022-03-16$7.97/sh1,512$12,05112,798 total
Footnotes (7)
  • [F1]This reflects the number of restricted stock units that became vested as of March 16, 2022.
  • [F2]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
  • [F3]Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
  • [F4]All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.
  • [F5]All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.
  • [F6]The exercise price of $10.25 represents a 25% premium over the fair market value of Axogen common stock on the date of the grant.
  • [F7]All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2026 (4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vest on March 16, 2023 and on each anniversary thereafter.

Issuer

Axogen, Inc.

CIK 0000805928

Entity typeother

Related Parties

1
  • filerCIK 0001764446

Filing Metadata

Form type
4
Filed
Mar 17, 8:00 PM ET
Accepted
Mar 18, 4:10 PM ET
Size
14.3 KB